Securities Fraud Investigation Into KinderCare Learning Companies, Inc. (KLC) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
IF YOU ARE AN INVESTOR WHO LOST MONEY ON KINDERCARE LEARNING COMPANIES, INC. (KLC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On April 3, 2025, the Bear Cave published a report alleging, among other things, that KinderCare 'fails to deliver the safe and nurturing environment it promises parents and taxpayers' and is 'a broken business that harms the children and families it claims to help.' Specifically, the report detailed several incidents of child neglect and abuse that had occurred at KinderCare daycares and stated that on several occasions, individuals employed by KinderCare were later arrested on charges of child sex abuse.
On this news, KinderCare's stock price fell $1.59, or 12.4%, to close at $11.19 per share on April 3, 2025, thereby injuring investors.
Then, on June 5, 2025, the Bear Cave published a second report stating that 'allegations against [KinderCare] are growing, [and] lawmakers are demanding accountability.' Specifically, the report cited a statement from a congresswoman questioning the continued federal funding of KinderCare.
On this news, KinderCare's stock price fell $0.63, or 5.5%, to close at $10.78 per share on June 5, 2025, thereby injuring investors further.
Contact Us To Participate or Learn More:
If you purchased KinderCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Plymouth Rises 47% on Receiving Acquisition Proposal From Sixth Street
Plymouth Industrial REIT PLYM recently announced that it has received an unsolicited, non-binding proposal from Sixth Street Partners, LLC, aimed at acquiring all of the outstanding shares of the company's common stock for a cash consideration of $24.10 per share. Shares of this industrial REIT witnessed a 47.06% rise in the regular trading session on the NYSE on Tuesday, following the announcement. As per the Schedule 13D filed with the U.S. Securities and Exchange Commission, which discloses the proposal, Sixth Street beneficially owns approximately 9.99% of Plymouth's outstanding common stock. In accordance with its fiduciary duties and following consultations with its financial and legal advisors, the company's board of directors will thoroughly review the proposal to ascertain the course of action that it considers to be in the best interests of all Plymouth shareholders. The company, which focuses on the acquisition, ownership and management of single- and multi-tenant industrial properties, noted that shareholders are not required to take any action at this time. Plymouth, with its opportunistic acquisitions and healthy leasing activity, is well-positioned to benefit. However, macroeconomic uncertainties and tariff issues remain a major concern in the near term. In the past three months, shares of this Zacks Rank #2 (Buy) company have rallied 36.7% against the industry's decline of 0.1%. Image Source: Zacks Investment Research Other Stocks to Consider Some other top-ranked stocks from the broader REIT sector are Host Hotels & Resorts HST and Welltower WELL, each carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for HST's 2025 FFO per share has moved 4 cents northward to $1.95 over the past month. The Zacks Consensus Estimate for WELL's 2025 FFO per share has moved 2 cents upward to $5.06 over the past week. Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Host Hotels & Resorts, Inc. (HST) : Free Stock Analysis Report Plymouth Industrial REIT (PLYM) : Free Stock Analysis Report Welltower Inc. (WELL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Key Points Pfizer's payout ratio is around 90% of earnings, which is high for a dividend stock. It reported strong operational growth of 10% in its most recent quarter. The company continues to focus on cutting costs to improve overall profitability. 10 stocks we like better than Pfizer › Finding a high-yielding stock that is safe to hang on to can be a rarity. When yields get high (e.g., more than 5%), usually there's a reason behind it. And investors are often hesitant to invest in such stocks, fearing that those incredibly attractive payouts may not end up being sustainable. One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, which is more than five times what the average rate is for the typical stock on the S&P 500 -- just 1.2%. Could Pfizer be one of the best dividend stocks to add to your portfolio right now, or is its yield too good to be true? Is Pfizer's high payout ratio a concern? A common metric to rely on when evaluating the safety of a dividend stock is its payout ratio. This tells you how much of a company's earnings are being paid out in the form of dividends. The higher it is, the more unsustainable the payout potentially is. Pfizer's payout ratio is currently around 90%, which suggests there isn't a big buffer in its bottom line. However, that number is skewed due to Pfizer's year-end results. In the last three months of 2024, the company incurred billions in asset impairment charges, restructuring expenses, and other non-cash items, which weighed down its earnings. And since the payout ratio looks at a company's earnings over the past 12 months, all it takes is one bad quarter to weigh it down. This is where relying on cash flow can be a better indicator of how healthy a dividend really is. In the trailing 12 months, Pfizer's free cash flow totaled $12.4 billion, which is far higher than the $9.6 billion it paid out in dividends over the past year. This implies the dividend is indeed safe. Recent results suggest the company is going in the right direction As of the end of last week, Pfizer's stock price is down 5% year to date, despite it already taking a beating in previous years. Investors remain concerned about not only its dividend, but also its growth potential. Pfizer is working to reduce costs while also growing its operations. Acquisitions, including its massive $43 billion purchase of oncology company Seagen in 2023, opened up new doors and opportunities for the business that look to be paying off. In its most recent quarter, which ended on June 29, the company reported year-over-year revenue growth of 10%, with sales topping $14.7 billion. Meanwhile, the company continues to reduce costs as it adapts to declining demand for its COVID-19 vaccine and pill. Its diluted earnings per share this past quarter totaled $0.51 -- higher than the rate of its quarterly dividend payment ($0.43). Pfizer's dividend looks safe, and the stock still looks cheap From looking at its financials, there aren't any glaring concerns to suggest that Pfizer's dividend is in trouble. I believe investors are being overly cautious with the stock. And with Pfizer focusing on cost reduction while also still growing its business, it's a top income-generating investment you can own for the long haul. It's currently trading at a price-to-earnings multiple of just 13, making it a fairly cheap stock to own. There are risks for many healthcare companies these days as healthcare reform may impact future profitability, but that can be difficult to predict and forecast. Pfizer is doing an excellent job of managing what it can control, and it's among the best stocks to buy in the healthcare sector. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True? was originally published by The Motley Fool
Business Insider
2 hours ago
- Business Insider
TD Cowen Keeps Their Hold Rating on McDonald's (MCD)
In a report released today, Andrew Charles from TD Cowen reiterated a Hold rating on McDonald's, with a price target of $315.00. The company's shares closed today at $313.08. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Charles covers the Consumer Cyclical sector, focusing on stocks such as Starbucks, Wingstop, and Dutch Bros Inc. According to TipRanks, Charles has an average return of 8.8% and a 53.65% success rate on recommended stocks. In addition to TD Cowen, McDonald's also received a Hold from Raymond James's Brian Vaccaro in a report issued today. However, on August 14, TR | OpenAI – 4o upgraded McDonald's (NYSE: MCD) to a Buy. The company has a one-year high of $326.32 and a one-year low of $276.53. Currently, McDonald's has an average volume of 3.64M. Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MCD in relation to earlier this year. Earlier this month, Edith Morgan Flatley, the EVP – Global CMO of MCD sold 976.00 shares for a total of $296,216.00.
